Keywords: دیابوکان; liposomes; encapsulation; toxicity; controlled release/delivery; injectables; stability; formulation; LUV AS; ammonium sulphate gradient liposomes; LUVDBCAS; ammonium sulphate gradient liposomes with dibucaine; AUEC; area under the effect curve; LUV 7.4;